Matinas biopharma reports q4 loss per share of $0.04

Matinas biopharma reports fourth quarter and full year 2019 financial results and operational highlights.q4 loss per share $0.04.q4 earnings per share estimate $-0.03 -- refinitiv ibes data.initiated enhance-it study of mat9001 against vascepa. topline data expected q4 2020.initiated efficacy phase of nih-funded enact study of mat2203 in cryptococcal meningitis q1 2020.matinas biopharma holdings - based on current projections, co believes that cash on hand is sufficient to fund operations into second half of 2022.matinas biopharma - plans to announce progression from cohort to cohort over course of 2020, but full data from mat2203 enact will not be available until second half 2021.
MTNB Ratings Summary
MTNB Quant Ranking